Rapid acute treatment of agitation in individuals with schizophrenia: Multicentre, randomised, placebo-controlled study of inhaled loxapine

British Journal of Psychiatry

Volumn 198, Issue 1, 2011, Pages 51-58

  Lesem, Michael D ^a   Tran Johnson, Tram K ^b   Riesenberg, Robert A ^c   Feifel, David ^d   Allen, Michael H ^e   Fishman, Robert ^f   Spyker, Daniel A ^f   Kehne, John H ^g   Cassella, James V ^f  

^a Claghorn Lesem Research Clinic Ltd   (United States)

^b CNRI San Diego   (United States)

^c Atlanta Center for Medical Research   (United States)

^d UCSD MEDICAL CENTER   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f Alexza Pharmaceuticals   (United States)

^g Translational Neuropharmacology Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; LORAZEPAM; LOXAPINE; PLACEBO; SALBUTAMOL;

ADULT; AGITATION; ARTICLE; BRONCHOSPASM; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DYSGEUSIA; DYSTONIA; FEMALE; GASTROENTERITIS; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; NAUSEA AND VOMITING; PHASE 3 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; WHEEZING;

ACUTE DISEASE; ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOXAPINE; MALE; MIDDLE AGED; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78651474093     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.110.081513     Document Type: Article

References (35)

1. Osser DN, Sigadel R. Short-term inpatient pharmacotherapy of schizophrenia. Harv Rev Psychiatry 2001; 9: 89-104.
2. Alderfer BS, Allen MH. Treatment of agitation in bipolar disorder across the life cycle. J Clin Psychiatry 2003; 64 (suppl 4): 3-9.
3. Battaglia J. The treatment of acute agitation in schizophrenia. CNS Spectr 2007; 12 (suppl 11): 4-5.
4. Currier GW, Trenton A. Pharmacological treatment of psychotic agitation. CNS Drugs 2002; 16: 219-28.
5. Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J 2003; 20: 339-46.
6. Currier GW, Allen MH, Bunney EB, Daniel DG, Francis A, Jagoda A, et al. Standard therapies for acute agitation. J Emerg Med 2004; 27 (suppl 4): s9-12.
7. Battaglia J. Pharmacological management of acute agitation. Drugs 2005; 65: 1207-22.
8. Citrome L. Interventions for the treatment of acute agitation. CNS Spectr 2007; 12 (suppl 11): 8-12.
9. Nordstrom K, Allen MH. Managing the acutely agitated and psychotic patient. CNS Spectr 2007; 12 (suppl 17): 5-11.
10. Zimbroff DL. Pharmacological control of acute agitation: focus on intramuscular preparations. CNS Drugs 2008; 22: 199-212.
11. Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP. The Expert Consensus Guideline Series. Treatment of behavioral emergencies. Postgrad Med 2001; May (special number): 1-88.
12. Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002; 59: 441-8.
13. Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007; 68: 111-9.
14. Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158: 1149-51.
15. Battaglia J, Lindborg SR, Alaka K, Meehan K, Wright P. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med 2003; 21: 192-8.
16. Heel RC, Brogden RN, Speight TM, Avery GS. Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent. Drugs 1978; 15: 198-217.
17. Chakrabarti A, Bagnall A, Chue P, Fenton M, Palaniswamy V, Wong W, et al. Loxapine for schizophrenia. Cochrane Database Syst Rev 2007; 4: CD001943.
18. Paprocki J, Versiani M. A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia. Curr Ther Res Clin Exp 1977; 21: 80-100.
19. Fruensgaard K, Korsgaard S, Jorgensen H, Jensen K. Loxapine versus haloperidol parenterally in acute psychosis with agitation. A double-blind study. Acta Psychiatr Scand 1977; 56: 256-64.
20. Dubin WR, Weiss KJ. Rapid tranquilization: a comparison of thiothixene with loxapine. J Clin Psychiatry 1986; 47: 294-7.
21. Gaussares C, Gerard H, Bosc M. Interest in injectable Loxapine for severe agitation. Inf Psychiatr 1989; 69: 656-60.
22. Bourdinard V, Pochard F. Survey of management methods for patients in a state of agitation at admissions and emergency departments in France. Encephale 2003; 29: 89-98.
23. Glazer WM. Does loxapine have "atypical" properties? Clinical evidence. J Clin Psychiatry 1999; 60 (suppl 10): 42-6.
24. Spyker DA, Munzar P, Cassella JV. Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol 2010; 50: 169-79.
25. Cassella J, Fishman R, Spyker D. AZ-004 Study Group. Inhaled loxapine rapidly improves acute agitation in schizophrenic patients. In Proceedings of the 162nd Annual Meeting of the American Psychiatric Association 2009: New Research Abstracts and Syllabus. Abstract NR7-005. Curran Associates, 2010.
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (4th edn) (DSM-IV). APA, 1994.
27. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76.
28. Kay SR. Significance of the positive-negative distinction in schizophrenia. Schizophr Bull 1990; 16: 635-52.
29. Rabinowitz JD, Lloyd PM, Munzar P, Myers DJ, Cross S, Damani R, et al. Ultrafast absorption of amorphous pure drug aerosols via deep lung inhalation. J Pharm Sci 2006; 95: 2438-51.
30. Rabinowitz JD, Wensley M, Lloyd P, Myers D, Shen W, Lu A, et al. Fast onset medications through thermally generated aerosols. J Pharmacol Exp Ther 2004; 309: 769-75.
31. Guy W. ECEU Assessment Manual for Psychopharmacology - Revised: 218-22. US Department of Health, Education, and Welfare, 1976.
32. Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley Jr CM, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacol 2002; 26: 494-504.
33. European Medicines Agency. ICH Topic E 6 (R1) Guideline for Good Clinical Practice. EMA, 2002 (http://www.ema.europa.eu/pdfs/human/ich/013595en.pdf).
34. Buckley PF. The role of typical and atypical antipsychotic medications in the management of agitation and aggression. J Clin Psychiatry 1999; 60 (suppl 10): 52-60.
35. Allen MH, Currier GW. Use of restraints and pharmacotherapy in academic psychiatric emergency services. Gen Hosp Psychiatry 2004; 26: 42-9.